Clinical Trials · NCT07790861
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 192
- Start date
- Dec 2026
- Locations
- 13 sites, China
- Primary endpoint
- Mean Percent Change From Baseline in Body Weight